Navigation Links
Researchers decipher modus operandi of potential Alzheimer's drug
Date:2/20/2013

s been collected so far. Furthermore, to date it was unknown, why methylene blue had the observed effect. "Methylene blue inhibits the aggregation process," Eckhard Mandelkow emphasizes. "But the way in which this happens was unknown until now."

The study now published in "Angewandte Chemie" reveals the nature of this process: Markus Zweckstetter's research group at the DZNE site in Gttingen and the Max Planck Institute for Biophysical Chemistry in Gttingen in collaboration with the Mandelkow team have been able to prove that methylene blue deactivates molecular residues which promote the bonding of tau proteins. Moreover, the researchers found indications that the substance acts as a spacer to keep the proteins apart. These findings could lead to the development of modified forms of methylene blue and new types of treatment.

Background:

Methylene blue tackles sulphur groups

NMR spectroscopy, a powerful technique for investigating biomolecules, was centrally important to the current study. "We found that methylene blue reacts with certain elements in the tau proteins called cysteines," Prof. Zweckstetter summarizes.

This reaction is highly effective. Methylene blue specifically modifies the tau proteins at critical spots: Of the up to 441 elements which a tau protein can consist of particularly the two cysteines are modified. The elements directly modified are the so-called SH groups, molecular appendages comprising sulphur and hydrogen which are typical of cysteines. Oxygen atoms now couple with them.

"This chemical transformation prevents tau proteins from bonding together," says Zweckstetter. "Otherwise SH groups from different proteins would react and form a so-called disulfide bridge. Now, this is no longer possible, because the reaction with methylene blue eliminates the SH groups."

In a healthy organism, the formation of these disulfide bridges is suppressed naturally. "The cell
'/>"/>

Contact: Dirk Frger
presse@dzne.de
49-228-433-02260
Helmholtz Association of German Research Centres
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Stanford researchers develop tool for reading the minds of mice
2. Researchers in Manchester find genetic key to preventing spine tumors
3. When It Comes To Genetic Code, Researchers Prove Optimum Isnt Always Best
4. UTSW researchers identify new enzyme that acts as innate immunity sensor
5. Researchers make racehorses fertile
6. USC researchers find possible genetic clues to organ development, birth defects
7. Researchers discover Achilles heel for lymphoid leukemia
8. Researchers find Asian needle ants displacing other aggressive invaders
9. Spanish researchers design biomarkers for the detection of dengue and West Nile virus
10. UT Dallas researchers pushing the boundaries of virtual reality
11. Polar bear researchers urge governments to act now and save the species
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2014)... , Dec. 08, 2014 Research and ... the addition of the "Biometrics Market in ... http://photos.prnewswire.com/prnh/20130307/600769 ... projects such as rural banking and upgradation of ... trends witnessed in the market. Besides the aforementioned ...
(Date:12/4/2014)... GARDENS, Fla. , Dec. 3, 2014 /PRNewswire/ ... solutions, today announced that its DigitalPersona ® ... fingerprint readers have been deployed throughout First Bank ... , South Carolina and ... in Southern Pines, North Carolina ...
(Date:11/21/2014)... -- Earlier this year Donald Spector , Chairman of ... the most prolific inventors in the world, got a ... to third party agencies. Spector envisioned this technology even ... earliest known patents in this area. Now major technology ... care, elder care and hospital applications. This technology has ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... technical, managerial and financial components of healthcare delivery to ... Disease) patient will be the topic of Stevens Institute ... October 31, 2007, from 3-5 p.m. in Room 122 ... Streets in Hoboken, NJ). , Roundtable participants will discuss ...
... a 46 percent increase in lifespan, raising the tantalizing ... are also taking an anti-aging medication. Results of the ... Lithgow, PhD, are currently published online in the Journal ... to treat mood affective disorders, including bipolar disease for ...
... daily commute may be taking more of a toll than ... of Southern California (USC) and the California Air Resources Board ... exposure to harmful air pollutants occurs while people are traveling ... spends about six percent (1.5 hours) of his or her ...
Cached Biology News:Stevens Health, Technology, and Society roundtable: Oct. 31 2Drug commonly used to treat bipolar disorder dramatically increases lifespan in worms 2Time spent in car drives up air pollution exposure 2
(Date:12/19/2014)... LayerBio is an MIT spin-off developing novel ... National Eye Institute (NEI) at the National Institutes of ... grant to develop a drug-eluting intraocular lens (IOL) for ... of vision loss in people over age 40 and ... Ken Mandell, LayerBio’s Founder and CEO, "There is a ...
(Date:12/19/2014)... December 19, 2014 The empty ... the rising ageing population and technological innovations in ... nutraceutical industries are catalysing the growth of the ... http://www.marketsandmarkets.com/Market-Reports/empty-capsules-market-218018190.html , Scope of Report , ... well as new entrants/smaller firms to gauge the ...
(Date:12/19/2014)... Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... pain, announced the results of its annual general meeting ... transformational year in Relmada,s history and it set the ... Sergio Traversa , chief executive officer of Relmada. ... financial, human resource and clinical development objectives that position ...
(Date:12/17/2014)... Ipsen Biopharmaceuticals, Inc., an affiliate ... IPSEY), today announced that Somatuline® Depot® (lanreotide) ... approved by the U.S. Food and Drug Administration ... (GEP-NETs) in adult patients with unresectable, well or ... improve progression-free survival (PFS). , “The approval of ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... DIEGO, INDIANAPOLIS and WALTHAM, Mass., March 10, 2011 ... Lilly and Company (NYSE: LLY ) and ... positive results from a phase 2 study evaluating the ... on glycemic control in patients with type 2 diabetes. ...
... 2011 Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: ... a randomized pivotal trial of pixantrone for the treatment ... the  U.S. Food and Drug Administration,s (the "FDA") Division ... trial, referred to as the PIX-R or PIX 306 ...
... release is available in German . , From the ... to the strings and sound box of a guitar or violin, ... actual mechanical vibrations of these instruments create acoustic waves that we ... related to the decay of the vibration amplitude, that is, the ...
Cached Biology Technology:Exenatide Once Monthly Showed Positive Results in Phase 2 Study 2Exenatide Once Monthly Showed Positive Results in Phase 2 Study 3Exenatide Once Monthly Showed Positive Results in Phase 2 Study 4Exenatide Once Monthly Showed Positive Results in Phase 2 Study 5Exenatide Once Monthly Showed Positive Results in Phase 2 Study 6Exenatide Once Monthly Showed Positive Results in Phase 2 Study 7FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial 2FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial 3FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial 4FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial 5How long does a tuning fork ring? 2
... The Zero Background/Kan Cloning Kit ... kanamycin resistance for selection in ... utilizes positive selection to eliminate ... all of the reagents you ...
GOAT ANTI SLI...
Protein Phosphorylation...
ANTI L-DOPA...
Biology Products: